Summary:
Phase 3 multicenter randomized 12weeks double blind paralled group placebo controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by 40 week double blind paralled group placebo controlled treatment periods.
Qualified Participants Must:
• Be 18 years of age or older
•.
Currently be on Schizophrenia medication
Speak English
•
Have a caregiver
Qualified Participants May Receive:
Free medical evaluation, free study medication, compensation for time and travel for patient and caregiver.